Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now early-phase tilt small index

Vasculitis: early-phase trial registry

7 of 12 indexed Vasculitis trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,429 of 28,707 conditions by registered trial count.

12 US clinical trials · 7 currently recruiting · #1,429 of 28,707 conditions by registered trial count

Vasculitis: 12 US clinical trials tracked, 7 recruiting.

Vasculitis is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 3 of these trials.

Enrollment posture brief

Registry condition vasculitis

OPEN 7 | RECR 58% | LATE 2 | EARLY 5 | RANK #1429 | SPON 3

Nearest open-share peer: Anterior Cruciate Ligament Reconstruction (58% recruiting · 12 trials)

Vasculitis (this)58%Acute Myeloid Leukemia in Re41.7%Adenocarcinoma of the Rectum41.7%Adherence, Patient16.7%Accelerated Phase Chronic My0%
Open-enrollment share among volume-matched conditions near Vasculitis

Vasculitis lists 7 open slots (58% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Vasculitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Vasculitis is recruiting above its size-band peers.

    7 of 12 indexed trials (58.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Vasculitis research.

    National Institute of Allergy and Infectious Diseases (NIAID) accounts for 3 of 12 trials (25%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Most Vasculitis trials plan to enrol fewer than 100 people.

    Median target enrolment is 50 among the 12 trials that report a genuine target (sentinel values excluded). 9 of those (75%) plan for fewer than 100 participants.

  4. Vasculitis splits between interventional and observational designs.

    7 interventional and 5 observational studies make up this index (58.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 23Phase 32

Open and recent trials

12 total, page 1 of 1

RECRUITING 300,000 participants

A Real-World Registry of Chronic Wounds and Ulcers

U.S. Wound Registry

NCT02280733

RECRUITING 100 participants

Longitudinal Study for Relapsing Polychondritis

University of Pennsylvania

NCT04919538

RECRUITING 100 participants

Vasculitis Pregnancy Registry

University of Pennsylvania

NCT02593565

RECRUITING 50 participants

Clinical Transcriptomics in Systemic Vasculitis (CUTIS)

Peter Merkel

NCT03004326

RECRUITING 40 participants

Longitudinal Study for Central Nervous System Vasculitis

University of Pennsylvania

NCT05734404

RECRUITING Phase 3 20 participants

Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.

Amgen

NCT06321601

RECRUITING Phase 1 8 participants

Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms

University of California, San Francisco

NCT02638701

ACTIVE NOT RECRUITING Phase 3 12 participants

The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach

University of South Florida

NCT01933724

COMPLETED Phase 2 75 participants

Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00004567

COMPLETED Phase 2 60 participants

Etanercept to Treat Wegener's Granulomatosis

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00001901

COMPLETED Phase 2 25 participants

Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation

National Heart, Lung, and Blood Institute (NHLBI)

NCT00005928

COMPLETED Phase 1 15 participants

Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00001761

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3
Phase 3 2

Named interventions

Most-linked intervention names on Vasculitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Interleukin-10 Drug
1 trials
Etanercept Drug
1 trials
0 mg prednisone Drug
1 trials
5 mg prednisone Drug
1 trials
Avacopan Drug
1 trials
Online questionnaires Other
1 trials
Ramipril Drug
1 trials
Infliximab Drug
1 trials

US sites by state

Facility locations filed on Vasculitis trials. A trial with sites in several states counts in each.

Pennsylvania 4 trials
Maryland 4 trials
Ohio 3 trials
Minnesota 3 trials
Texas 2 trials
Florida 2 trials
California 2 trials
Virginia 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Vasculitis page

12 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Vasculitis condition card totals 12 registered trials; most-linked intervention Interleukin-10; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.